明基医院招股结果进一步显示，本次募资总额约6.26亿港元，净额约5.55亿港元。本次募资资金，计划用于医院扩建、智慧医院系统升级及并购储备。其 中，南京明基医院二期工程将强化区域医疗资源供给，提升智慧医疗服务能力，助力河西新城医疗配套升级。 据悉，作为建邺区重点民营医疗机构，南京明基医院位于河西大街71号，2008年开始运营，2022年获评三级甲等，为江苏省首家民营三甲医院。根据弗若 斯特沙利文的数据，以2024年总收入26.59亿元计，南京明基医院是中国第三大民营营利性综合医院，也是江苏省最大的民营营利性综合医院。此外，南 京明基医院还是中国首批国家胸痛中心认证单位、"全国健康管理示范基地"，拥有多个国家级及省级重点科室。 今年以来，南京企业 进军资本市场按下"加速键" 12月22日，明基医院集团股份有限公司（以下简称明基医院）成功在香港联交所主板挂牌上市，集资总额超6亿港元，为国际资本市场增添一股蕴含南京 基因的优质民营医院价值样本。 明基医院是中国内地大型民营营利性综合医院集团，旗下运营南京明基医院和苏州明基医院，是华东地区最大的民营营利性综合医院集团。截至今年6月 30日，明基医院两家医院总建筑面积合 ...

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing up 0.43% at 25,801.77 points and a total trading volume of HKD 169.77 billion [1] - The market is currently in a left-side layout phase, with strong expectations for a spring rally, although there are supply and demand pressures towards the end of the year [1] Blue Chip Performance - Semiconductor company SMIC (00981) led blue-chip gains, rising 5.92% to HKD 68.9, contributing 27.67 points to the Hang Seng Index [2] - Other notable blue-chip performers included Zijin Mining (02899) up 5.3% and Pop Mart (09992) up 4.61%, while WuXi AppTec (02359) and Hang Lung Properties (00101) saw declines [2] Sector Highlights - Large technology stocks generally rose, with Alibaba up 0.76% and Tencent up 0.08% [3] - The metals sector saw significant gains, with gold prices surpassing USD 4,400 per ounce and LME copper prices nearing USD 12,000 per ton [4] - The new consumption sector was active, with companies like Mixue Group (02097) rising 10.13% following the opening of a new store in Los Angeles [6] Investment Opportunities - The storage and advanced process sectors are expected to see accelerated growth, benefiting domestic equipment manufacturers [5] - The AI and robotics sectors are gaining traction, with companies like Ubiquiti (09880) and others seeing increased orders and market interest [6][7] New Stock Listings - Four new stocks listed on the Hong Kong market faced significant declines on their debut, with Mindray Hospital (02581) dropping 49.46% [8] - China Duty Free Group (01880) saw a strong performance, rising 15.77% amid positive sales data from Hainan's duty-free shopping [9] Company-Specific Developments - Yujian (02432) faced downward pressure due to an upcoming lock-up expiration and a recent share placement [10]

资料显示，明基医院是一家民营营利性综合医院集团，目前拥有和运营两家综合医院，分别为南京明基 医院和苏州明基医院，收入主要来自提供综合医疗服务，包括住院医疗服务及门诊医疗服务。 北京商报讯（记者 丁宁）12月22日，明基医院（02581.HK）登陆港交所，上市首日，明基医院股价大 跌，收跌49.46%，收盘价为4.72港元/股。 今年上半年，明基医院营收、净利双降。财务数据显示，今年上半年，公司实现的营业收入约为13.12 亿元，同比下降1.34%；归属净利润约为4870万元，同比下降23.18%。 ...

今日港股四只新股上市首日集体破发。截至收盘，明基医院(02581.HK)、印象大红袍(02695.HK)、华芢 生物(02396.HK)、南华期货(02691.HK)分别下跌49.46%、35.28%、29.32%和24.17%。据Wind数据显 示，明基医院今日跌幅已超海螺材料科技(02560.HK)1月9日47.67%的跌幅，创下年内港股新股首日最差 表现。 ...

中国经济网北京12月22日讯 明基医院集团股份有限公司（以下简称"明基医院"，02581.HK）今日 在港交所上市。明基医院开盘即破发，报6.5港元，截至收盘报4.72港元，跌幅49.46%。 | 發售股份及股本 | | | --- | --- | | 發售股份數目 | 67,000,000 | | 香港公開發售的最終發售股份數目 | 6,700,000 | | 國際發售的最終發售股份數目 | 60,300,000 | | 上市後已發行股份數目 | 311,945,001 | 最终发售价及分配结果公告显示，明基医院全球发售项下的发售股份数目67,000,000股股份，其中 香港发售股份数目6,700,000股股份，国际发售股份数目60,300,000股股份。 明基医院的联席保荐人、整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人为中国 国际金融香港证券有限公司、花旗环球金融亚洲有限公司，联席全球协调人、联席账簿管理人及联席牵 头经办人为中国信托商业银行股份有限公司，联席账簿管理人及联席牵头经办人为富途证券国际（香 港）有限公司、利弗莫尔证券有限公司、TradeGo Markets Limited、大 ...

Group 1 - The Hang Seng Index rose by 0.20%, gaining 51 points to close at 25,742 points, while the Hang Seng Tech Index increased by 0.89% [1] - China Duty Free Group (01880) surged by 12% as duty-free shopping on Hainan's first day of closure increased by 61% year-on-year [1] - Lithium stocks continued to rise, with Tianqi Lithium (09696) up over 5% due to expectations of resumption of production, and Ganfeng Lithium (01772) increasing by 4.84% [1] - Jiaxin International Resources (03858) rose over 10% to reach a new high, benefiting from a more than 220% increase in tungsten powder prices this year [1] - Spot gold reached a new historical high, with Goldman Sachs reaffirming a bullish outlook on gold, leading to significant gains in gold stocks such as Lingbao Gold (03330) up 6.8% and China Gold International (02099) up 6.2% [1] - The optical communication sector showed strong performance, with Huiju Technology (01729) rising over 13% due to breakthroughs in optical computing chips, and Changfei Optical Fiber (06869) increasing by 11.01% [1] - Chip stocks strengthened in early trading, with the National Integrated Circuit Investment Fund's third phase focusing on IC substrate fields, leading to a rise of over 7% for SMIC (00981) and 5% for Hua Hong Semiconductor (01347) [1] - Pony.ai-W (02026) increased by over 9%, achieving single-vehicle profitability in Guangzhou, with two models of its seventh-generation vehicle now in production [1] Group 2 - Guoxia Technology (02655) surged over 16% as the company enters a new phase of global development, focusing on deepening "AI+" core technology research in energy storage [2] - WanGuo Gold Group (03939) rose nearly 7%, with its subsidiary Jinling Mining expected to become a world-class gold mine [3] - Goldwind Technology (02208) increased by nearly 5% as domestic wind turbine bidding prices recovered, with institutions optimistic about the profitability recovery of wind turbine manufacturers [4] - Four new stocks listed all fell below their issue prices, with Impression Dahongpao (02695) dropping 25%, Mingji Hospital (02581) down 42%, and Huazhi Biotechnology-B (02396) declining over 8% [4]

Core Viewpoint - Ming Chi Hospital (2581.HK) experienced a significant drop on its first day of trading, falling over 43% to HKD 5.28, resulting in a market capitalization of HKD 1.64 billion, despite an IPO pricing of HKD 9.34 and a public offering subscription rate of 6.28 times [1] Financial Performance - The company's revenue increased from HKD 2,336.4 million in 2022 to HKD 2,687.6 million in 2023, with a slight decrease projected to HKD 2,659.0 million in 2024 [1] - The gross profit margin improved from 16.4% in 2022 to 18.9% in 2023, with a forecasted decline to 18.1% in 2024 [1] - Net profit for the years 2022, 2023, and 2024 was reported at HKD 89.6 million, HKD 167.5 million, and HKD 108.9 million respectively, with net profit margins of 3.8%, 6.2%, and 4.1% for the same years [1]

Group 1: Stock Market Performance - The Hang Seng Index rose by 0.20%, gaining 51 points to close at 25,742 points, while the Hang Seng Tech Index increased by 0.89% [1] - The Hong Kong stock market saw a trading volume of HKD 95.5 billion in the morning session [1] Group 2: Company Highlights - China Duty Free Group (01880) surged by 12% as duty-free shopping on the first day of Hainan's closure increased by 61% year-on-year [1] - Tianqi Lithium (09696) rose over 5% due to expectations of resumption of production following environmental assessment information disclosure [1] - Ganfeng Lithium (01772) increased by 4.84% [1] - Jiaxin International Resources (03858) climbed over 10%, reaching a new high, benefiting from a more than 220% increase in tungsten powder prices this year [1] - Gold stocks performed well, with Lingbao Gold (03330) rising by 6.8% and China Gold International (02099) increasing by 6.2% as spot gold reached a historical high [1] - Huizhu Technology (01729) surged over 13% due to breakthroughs in optical computing chip technology [1] - Zhongke Semiconductor (00981) rose over 7% as the National Integrated Circuit Investment Fund's third phase focuses on IC substrate [1] - Pony.ai-W (02026) increased by over 9%, achieving single-vehicle profitability in Guangzhou with two models of its seventh-generation vehicle in production [1] - Guoxia Technology (02655) surged over 16% as the company enters a new phase of global development, focusing on "AI+" energy storage core technology [2] - WanGuo Gold Group (03939) rose nearly 7% as its subsidiary Jinling Mining is expected to become a world-class gold mine [3] - Goldwind Technology (02208) increased nearly 5% as domestic wind turbine bidding prices recover, with institutions optimistic about the profitability of wind turbine manufacturers [4] Group 3: IPO Performance - Four new stocks listed all experienced declines, with Impression Dahongpao (02695) dropping by 25%, Mingji Hospital (02581) falling by 42%, and Huazhi Biotechnology-B (02396) decreasing by over 8% [4]

Group 1: New Stock Listings Performance - Four new stocks, including Impression Da Hong Pao, Huazhang Biotech, Mingji Hospital, and Nanhua Futures, debuted but all experienced a decline on their first trading day [1] Group 2: Huazhang Biotech - Huazhang Biotech opened at HKD 33.8, which is 11.5% lower than the IPO price of HKD 38.2, resulting in a loss of HKD 880 per lot of 200 shares [2] - The company focuses on wound healing therapies and is an unprofitable biotech firm specializing in developing protein drugs, particularly platelet-derived growth factor (PDGF) drugs [2] - The company did not attract cornerstone investors, with Huatai International and CITIC Securities serving as joint sponsors [3] Group 3: Mingji Hospital - Mingji Hospital opened at HKD 6.5, down 30.4% from the IPO price of HKD 9.34, leading to a loss of HKD 1,420 per lot of 500 shares [4] - The company operates as a large private profit-oriented hospital group in East China, primarily managing two tertiary hospitals in Nanjing and Suzhou, with a focus on orthopedics, cardiovascular, oncology, and reproductive medicine [4] - Cornerstone investors include He Rong Technology, He Fu (China), and Suzhou Zhanxing, collectively subscribing to 49.63% of the total offering [5] Group 4: Impression Da Hong Pao - Impression Da Hong Pao opened at HKD 3.26, which is 9.4% lower than the IPO price of HKD 3.6, resulting in a loss of HKD 340 per lot of 1,000 shares [6] - The company operates based on Wuyi Mountain tea culture, providing tourism performances and related services, with its core revenue source being the live performance "Impression Da Hong Pao," accounting for over 85% of its income [6] - The company was oversubscribed by over 3,400 times, with joint sponsors being Xingsheng International and Kaisen [6] Group 5: Nanhua Futures - Nanhua Futures opened at HKD 9.13, down 23.9% from the IPO price of HKD 12, leading to a loss of HKD 1,435 per lot of 500 shares [7] - The company is a futures brokerage listed on the A-share main board, primarily engaged in futures brokerage, investment consulting, asset management, and securities investment fund distribution, focusing on derivative business [7] - CITIC Securities is the sole sponsor for the company [7]

Core Viewpoint - The recent IPO of Ming Kee Hospital (02581.HK) and three other stocks on the Hong Kong Stock Exchange faced significant declines on their debut, with Ming Kee Hospital experiencing the largest drop of over 38.5% from its issue price of 9.34 HKD to approximately 5.74 HKD [2][3]. Group 1: IPO Performance - Four new stocks, including Ming Kee Hospital, were listed on December 22, with all experiencing a drop on their first trading day [2]. - Ming Kee Hospital had a subscription rate of 6.28 times during the public offering phase, with 670,000 shares allocated, representing about 10% of the total shares [2]. - The international placement phase saw a subscription rate of 1.28 times, with 60.3 million shares allocated, accounting for 90% of the total shares [2]. Group 2: Company Overview - Ming Kee Hospital is a private profit-oriented general hospital group in mainland China, operating two hospitals with a total of 1,850 registered beds and over 1,000 experienced doctors, including 35 experts from Taiwan and overseas [3]. - The hospital group is projected to serve over 2 million outpatient visits and perform over 22,000 inpatient surgeries in 2024 [3]. - According to Frost & Sullivan, Ming Kee Hospital is the largest private profit-oriented general hospital group in East China, holding a market share of 1.0% based on total revenue for 2024 [3]. Group 3: Financial Performance - Ming Kee Hospital's revenue from 2022 to the first half of 2025 is projected to be 2.336 billion RMB, 2.688 billion RMB, 2.659 billion RMB, and 1.312 billion RMB, respectively, with corresponding profits of 90 million RMB, 167 million RMB, 109 million RMB, and 49 million RMB [3]. - There has been a noticeable decline in profit performance in recent years [3].